A novel assay for true live single circulating tumor cell (CTC) capture was developed to isolate individual tumor cells from blood samples with zero leukocyte contamination, enabling ultra-high purity liquid biopsy analysis.
The advanced CTC isolation platform preserves viable single tumor cells, allowing accurate downstream molecular characterization while maintaining cellular integrity for research and diagnostic applications.
By eliminating background leukocyte contamination, the assay significantly improves the sensitivity and reliability of single-cell genomics and multi-omics profiling compared with conventional CTC capture technologies.
The platform supports integrated multi-omics analysis, including genomics, transcriptomics, and proteomics, enabling comprehensive molecular profiling of circulating tumor cells.
Scalability of the technology was demonstrated across a large and diverse cancer patient population, highlighting its potential for broad clinical adoption in oncology research and diagnostics.
High-purity single-cell CTC isolation enables deeper insights into tumor heterogeneity, clonal evolution, and therapy resistance, which are critical for understanding cancer progression.
The technology strengthens liquid biopsy–based disease monitoring, supporting applications such as treatment response evaluation, minimal residual disease detection, and metastatic risk assessment.
This next-generation single-CTC capture technology advances precision oncology diagnostics, facilitating biomarker discovery and personalized cancer treatment strategies. Read Abstract